Amicus Therapeutics, Inc. (FOLD) Reaches $9.78 52-Week High; Profile of 3 Analysts Covering Bright Horizons Family Solutions (BFAM)

June 19, 2017 - By Nellie Frank

Among 6 analysts covering Bright Horizons (NYSE:BFAM), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Bright Horizons had 12 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of Bright Horizons Family Solutions Inc (NYSE:BFAM) has “Overweight” rating given on Wednesday, November 25 by Barclays Capital. The stock has “Outperform” rating by Credit Suisse on Wednesday, February 3. William Blair downgraded Bright Horizons Family Solutions Inc (NYSE:BFAM) on Friday, February 10 to “Market Perform” rating. The rating was maintained by RBC Capital Markets on Wednesday, August 5 with “Outperform”. RBC Capital Markets maintained the shares of BFAM in report on Monday, November 9 with “Outperform” rating. Credit Suisse downgraded Bright Horizons Family Solutions Inc (NYSE:BFAM) on Friday, May 12 to “Neutral” rating. The rating was downgraded by William Blair to “Market Weight” on Wednesday, November 2. JP Morgan upgraded the shares of BFAM in report on Monday, August 15 to “Overweight” rating. The firm has “Outperform” rating given on Tuesday, February 9 by RBC Capital Markets. See Bright Horizons Family Solutions Inc (NYSE:BFAM) latest ratings:

12/05/2017 Broker: Credit Suisse Old Rating: Outperform New Rating: Neutral Downgrade
10/02/2017 Broker: William Blair Old Rating: Outperform New Rating: Market Perform Downgrade

The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) hit a new 52-week high and has $10.46 target or 7.00% above today’s $9.78 share price. The 6 months bullish chart indicates low risk for the $1.50 billion company. The 1-year high was reported on Jun, 19 by Barchart.com. If the $10.46 price target is reached, the company will be worth $105.00M more. About 992,898 shares traded. Amicus Therapeutics, Inc. (NASDAQ:FOLD) has risen 12.45% since June 19, 2016 and is uptrending. It has underperformed by 4.25% the S&P500.

Among 7 analysts covering Amicus Therapeutics (NASDAQ:FOLD), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Amicus Therapeutics has $28 highest and $8 lowest target. $14.50’s average target is 48.26% above currents $9.78 stock price. Amicus Therapeutics had 12 analyst reports since August 18, 2015 according to SRatingsIntel. The rating was upgraded by Chardan Capital Markets to “Buy” on Monday, October 5. The rating was downgraded by Chardan Capital Markets on Wednesday, September 16 to “Neutral”. The stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) earned “Outperform” rating by Leerink Swann on Monday, October 5. The stock has “Neutral” rating by Goldman Sachs on Wednesday, March 30. Robert W. Baird upgraded it to “Outperform” rating and $10 target in Tuesday, January 24 report. Cowen & Co maintained Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Tuesday, September 1 with “Buy” rating. The rating was initiated by Bank of America on Wednesday, May 18 with “Buy”. JP Morgan maintained the stock with “Overweight” rating in Tuesday, September 8 report. The firm earned “Buy” rating on Tuesday, August 18 by Zacks. Robert W. Baird initiated Amicus Therapeutics, Inc. (NASDAQ:FOLD) on Thursday, April 14 with “Neutral” rating.

Amicus Therapeutics, Inc. is a biotechnology company. The company has market cap of $1.50 billion. The Firm is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. It currently has negative earnings. The Company’s lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for Fabry disease.

Since December 22, 2016, it had 4 insider buys, and 5 sales for $1.26 million activity. Another trade for 29,914 shares valued at $239,312 was made by Do Hung on Friday, May 19. On Thursday, December 22 the insider PERCEPTIVE ADVISORS LLC bought $854,835. 49,050 shares were sold by Campbell Bradley L, worth $392,400.

Investors sentiment decreased to 1.24 in 2016 Q4. Its down 0.25, from 1.49 in 2016Q3. It fall, as 27 investors sold Amicus Therapeutics, Inc. shares while 32 reduced holdings. 25 funds opened positions while 48 raised stakes. 151.10 million shares or 5.89% more from 142.70 million shares in 2016Q3 were reported. Nj State Employees Deferred Compensation Plan, New Jersey-based fund reported 15,000 shares. Price T Rowe Associates Incorporated Md has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Principal Fincl Grp Inc stated it has 26,396 shares. Qs Invsts Ltd Co stated it has 183,324 shares. Brown Advisory Inc has invested 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Citadel Ltd Llc reported 307,051 shares. Tower Research Capital Ltd Limited Liability Company (Trc) holds 0% in Amicus Therapeutics, Inc. (NASDAQ:FOLD) or 2,340 shares. Artal Group Sa reported 1.75 million shares. Royal Comml Bank Of Canada reported 0% stake. Rock Springs Cap Mngmt Lp owns 757,500 shares or 0.25% of their US portfolio. Jennison Assoc Ltd Liability Company reported 0.05% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD). Edge Wealth Management Ltd Liability Corporation reported 1,000 shares stake. Moreover, Morgan Stanley has 0% invested in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 3.07M shares. Proshare Lc stated it has 116,911 shares. Pnc Fin holds 0% of its portfolio in Amicus Therapeutics, Inc. (NASDAQ:FOLD) for 16,907 shares.

Bright Horizons Family Solutions Inc. is a well-known provider of child care, early education and other services. The company has market cap of $4.60 billion. The Firm provides services under multi-year contracts with employers offering child care and other dependent care solutions as part of their employee benefits packages. It has a 42.09 P/E ratio. The Company’s divisions include full service center care services, back-up dependent care services and other educational advisory services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: